Company / FCF Margin
ADMA Biologics, Inc. FCF Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest FCF Margin
5.5%
FY2025
5-year range
-155.5% / 25.9%
FY2021-FY2025
Trend
-79.0%
vs FY2024
Sector context
#53 of 133
Health Care
What the data says
At 5.5%, ADMA Biologics, Inc.'s fcf margin ranks #53 of 133 in the Health Care sector. Improved from 1.6% to 5.5% over the past 2 years.
Based on SEC 10-K filings.
5.5% in FY2025 with a 5-year CAGR of +277.2%.
Improved from 1.6% to 5.5% over the past 2 years.
Health Care sector context is included.
FCF Margin over time
Growth rates
- 3-Year Change
- +161.0pp
- 5-Year Change
- +277.2pp
- 10-Year Change
- -
Sector benchmark
#53 of 133 in Health CareTop 40% of 133This company 5.5% Sector average -632.8%
▼
+100.9% above sector average
Key checks
Key Insights
- In FY2025, fcf margin decreased 79.0% year-over-year.
- Currently 638.3pp above the Health Care sector average.
- Peak fcf margin was recorded in FY2024.
- Lowest fcf margin in the period was in FY2018.
Company context
Key Data Points
- Altman Z-Score 3.37 (safe zone, above 2.9 threshold)
- Strong profit margin: 46.4%
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | FCF MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | 5.5% | -79.0% |
| FY2024 | 25.9% | +1560.3% |
| FY2023 | 1.6% | +101.0% |
| FY2022 | -155.5% | +0.0% |
| FY2021 | -155.5% | +42.8% |
| FY2020 | -271.7% | +0.3% |
| FY2019 | -272.6% | +28.5% |
| FY2018 | -381.4% | -121.7% |
| FY2017 | -172.0% | +0.0% |
| FY2016 | -172.0% | +40.2% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026